Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)

Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q.H. Wang; Piero Portincasa

doi:10.1007/978-1-0716-1433-4_12

Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)

Ignazio Grattagliano, Agostino Di Ciaula, Jacek Baj, Emilio Molina-Molina, Harshitha Shanmugam, Gabriella Garruti, David Q.H. Wang, Piero Portincasa

Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

8 Scopus citations

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.

Original language	English (US)
Title of host publication	Methods in Molecular Biology
Publisher	Humana Press Inc.
Pages	201-246
Number of pages	46
DOIs	https://doi.org/10.1007/978-1-0716-1433-4_12
State	Published - 2021

Publication series

Name	Methods in Molecular Biology
Volume	2310
ISSN (Print)	1064-3745
ISSN (Electronic)	1940-6029

Keywords

Fatty liver
Mitochondria
Nitrosative stress
Nonalcoholic fatty liver disease
Oxidative stress

ASJC Scopus subject areas

Molecular Biology
Genetics

Access to Document

10.1007/978-1-0716-1433-4_12

Cite this

Grattagliano, I., Di Ciaula, A., Baj, J., Molina-Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. H., & Portincasa, P. (2021). Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). In Methods in Molecular Biology (pp. 201-246). (Methods in Molecular Biology; Vol. 2310). Humana Press Inc.. https://doi.org/10.1007/978-1-0716-1433-4_12

Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). / Grattagliano, Ignazio; Di Ciaula, Agostino; Baj, Jacek et al.
Methods in Molecular Biology. Humana Press Inc., 2021. p. 201-246 (Methods in Molecular Biology; Vol. 2310).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Grattagliano, I, Di Ciaula, A, Baj, J, Molina-Molina, E, Shanmugam, H, Garruti, G, Wang, DQH & Portincasa, P 2021, Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). in Methods in Molecular Biology. Methods in Molecular Biology, vol. 2310, Humana Press Inc., pp. 201-246. https://doi.org/10.1007/978-1-0716-1433-4_12

@inbook{a9493c80d261406cac04c17ede7c4342,

title = "Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)",

abstract = "Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.",

keywords = "Fatty liver, Mitochondria, Nitrosative stress, Nonalcoholic fatty liver disease, Oxidative stress",

author = "Ignazio Grattagliano and {Di Ciaula}, Agostino and Jacek Baj and Emilio Molina-Molina and Harshitha Shanmugam and Gabriella Garruti and Wang, {David Q.H.} and Piero Portincasa",

note = "Funding Information: These projects received funding from the European Union{\textquoteright}s Horizon 2020 Research and Innovation program under the Marie Sk{\l}odowska-Curie Grant Agreement No. 722619 (FOIE GRAS) and Grant Agreement No. 734719 (mtFOIE GRAS). EMM and HS are recipients of Marie Sk{\l}odowska-Curie Grant Agreement No. 722619. This chapter is dedicated to Prof. Giuseppe Palasciano and Prof. Sergio Papa (University of Bari, Italy), Prof. Hermon Dowling (University of London, UK), Prof. Gerard P. vanBerge-Henegouwen (Utrecht University, The Netherlands), and Prof. Tom LaMont (Harvard Medical School, Boston, USA). We are indebted to Prof. Salvatore Passarella (University of Foggia, Italy) for helpful scientific discussion. Publisher Copyright: {\textcopyright} 2021, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

doi = "10.1007/978-1-0716-1433-4_12",

language = "English (US)",

series = "Methods in Molecular Biology",

publisher = "Humana Press Inc.",

pages = "201--246",

booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)

AU - Grattagliano, Ignazio

AU - Di Ciaula, Agostino

AU - Baj, Jacek

AU - Molina-Molina, Emilio

AU - Shanmugam, Harshitha

AU - Garruti, Gabriella

AU - Wang, David Q.H.

AU - Portincasa, Piero

N1 - Funding Information: These projects received funding from the European Union’s Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie Grant Agreement No. 722619 (FOIE GRAS) and Grant Agreement No. 734719 (mtFOIE GRAS). EMM and HS are recipients of Marie Skłodowska-Curie Grant Agreement No. 722619. This chapter is dedicated to Prof. Giuseppe Palasciano and Prof. Sergio Papa (University of Bari, Italy), Prof. Hermon Dowling (University of London, UK), Prof. Gerard P. vanBerge-Henegouwen (Utrecht University, The Netherlands), and Prof. Tom LaMont (Harvard Medical School, Boston, USA). We are indebted to Prof. Salvatore Passarella (University of Foggia, Italy) for helpful scientific discussion. Publisher Copyright: © 2021, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2021

Y1 - 2021

N2 - Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.

KW - Fatty liver

KW - Mitochondria

KW - Nitrosative stress

KW - Nonalcoholic fatty liver disease

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85107782221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107782221&partnerID=8YFLogxK

U2 - 10.1007/978-1-0716-1433-4_12

DO - 10.1007/978-1-0716-1433-4_12

M3 - Chapter

C2 - 34096005

AN - SCOPUS:85107782221

T3 - Methods in Molecular Biology

SP - 201

EP - 246

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)

Abstract

Publication series

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this